LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
University of Illinois licenses novel anti-cancer therapies to StemPar Sciences
StemPar Sciences, Inc., the University of Illinois at Urbana-Champaign (Illinois), and the University of Texas Southwestern Medical Center (UTSW) have entered into a license agreement through which StemPar Sciences plans to develop cancer therapeutics based on compounds designed by Professor Paul Hergenrother of the Department of Chemistry at the University of Illinois at Urbana-Champaign, and Professor David Boothman, the Robert B. and Virginia Payne Professor in Oncology and Associate Director for Translation Research at UTSW.

The quinone-based compounds exhibited potent anti-cancer activity by inducing programed necrosis, meaning they activate the molecular pathway that causes the premature death of cancerous cells and tissue. The potency and selectivity of these new compounds rival commonly used chemotherapy agents by targeting solid tumors that have elevated levels of the enzyme NAD(P)H:quinone oxioreductase 1 (NQO1). Research indicates that the compounds are able to target a range of solid tumors that are considered difficult to treat, including pancreatic and lung cancers. Furthermore, research suggests that this new class of quinone-based compounds express greater potency than other molecules in the same class, such as β-lapachone. These findings, published in the journal Cancer Research, have shown great promise in pre-clinical testing in mice.

“We view this exclusive worldwide license as an important part of our growing cancer metabolism IP estate,” said StemPar CEO Barry Sherman, MD. “Indeed, this intellectual property has the potential to become a vital ingredient in the quest to develop novel cancer medicines based on the science of cancer metabolism.”

“We are proud to partner with StemPar Sciences to advance this promising research into new cancer therapies,” said Jen Rice, Technology Manager at Illinois’ Office of Technology Management. “We believe the alliance leverages our complementary strengths and will accelerate the development of powerful new therapeutics.”

Click here for the complete issue.


Credits to: American Chemical Society

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy